Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trialXiaotian Zhang, Jiafu Ji, Zhaode Bu et al.|The Lancet Oncology|2021Cited by 436
Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trialLai Xu, Xiangqian Su, Zirui He et al.|The Lancet Oncology|2021Cited by 184
Extent of Lymphadenectomy for Surgical Management of Right-Sided Colon Cancer: The Randomized Phase III RELARC TrialJunyang Lu, Ang Li, Jiadi Xing et al.|Journal of Clinical Oncology|2024Cited by 43
Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cellsDaguang Wang, Jian Suo|International Journal of Molecular Medicine|2018Cited by 16